Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant serplulimab + SOX with or without lymph node–sparing SCRT in upper gastric/GEJ adenocarcinoma
ChiCTR2600123881Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of serplulimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tongji Hospital. Primary endpoint: Pathological complete response (pCR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600123881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123881.